Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 15/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31311299 | 0.94 | ALOX12 (0.37) | ALOX12ALOX15ALDH1A1LMNAGAA | |
| SCHEMBL31311442 | 0.90 | ALOX12 (0.47) | ALOX12ALOX15ALDH1A1LMNAGAA | |
| SCHEMBL31311209 | 0.89 | MAPT (0.38) | ALOX12ALOX15ALDH1A1LMNAGAA | |
| SCHEMBL31311286 | 0.88 | ALOX12 (0.39) | ALOX12ALOX15ALDH1A1LMNAGAA | |
| SCHEMBL31311260 | 0.86 | PTGS1 (0.39) | ALOX12ALOX15ALDH1A1LMNAGAA | |
| SCHEMBL31311305 | 0.85 | PTGS1 (0.37) | ALOX12ALOX15ALDH1A1LMNAGAA | |
| SCHEMBL31311159 | 0.85 | PTGS1 (0.38) | ALOX12ALOX15ALDH1A1LMNAGAA | |
| SCHEMBL31311310 | 0.84 | ALOX12 (0.36) | ALOX12ALOX15ALDH1A1LMNAGAA | |
| SCHEMBL31311313 | 0.83 | MAPT (0.42) | ALOX12ALOX15ALDH1A1LMNAGAA | |
| SCHEMBL31311301 | 0.83 | ALOX12 (0.47) | ALOX12ALOX15ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024264032-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | disclosed |